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Expansion of the pancreatic endocrine cell population occurs during both embryonic development and
during post-natal pancreatic growth and regeneration. Mechanisms of the expansion of endocrine cells
during embryonic development are not completely understood, and no clear mechanistic link has been
established between growth of the embryonic endocrine pancreas and the islet cell replication that
occurs in an adult animal. We found that transforming growth factor-beta (TGF-β) superfamily signaling,
which has been implicated in many developmental processes, plays a key role in regulating pancreatic
endocrine maturation and development. Speciﬁcally, the intracellular mediators of TGF-β signaling,
smad2 and smad3, along with their inhibitor smad7, appear to mediate this process. Smad2, smad3 and
smad7 were all broadly expressed throughout the early embryonic pancreatic epithelium. However,
during later stages of development, smad2 and smad3 became strongly localized to the nuclei of the
endocrine positive cells, whereas the inhibitory smad7 became absent in the endocrine component.
Genetic inactivation of smad2 and smad3 led to a signiﬁcant expansion of the embryonic endocrine
compartment, whereas genetic inactivation of smad7 led to a signiﬁcant decrease in the endocrine
compartment. In vitro antisense studies further corroborated these results and supported the possibility
that interplay between the inhibitory smad7 and the intracellular mediators smad2/3 is a control point
for pancreatic endocrine development. These results should provide a better understanding of the key
control mechanisms for β-cell development.
& 2013 Elsevier Inc. All rights reserved.Introduction
The pancreas is an endodermally derived organ consisting of
two morphologically and functionally distinct tissues, the exocrine
and endocrine pancreas. During embryonic growth, the pancreas
goes through three stages of development. The ﬁrst is a relatively
undifferentiated stage where pancreatic morphogenesis is
initiated with endodermal evagination. The second stage involves
epithelial branching morphogenesis, which also includes the
delamination of differentiating islet progenitors from the base-
ment membrane. The ﬁnal stage begins with the formation of
acinar cells at the apices of the ductal structures. During these
stages, the endocrine compartment undergoes ampliﬁcationll rights reserved.
-Gohary),
aper.during two distinct waves of differentiation. The primary wave
(pre-E13.5) is followed by the secondary wave of differentiation
from the ducts (E13.5-E16.5)(Edlund, 2001; Prasadan et al., 2002).
Speciﬁc factors governing this endocrine expansion are a subject of
active study.
We have previously investigated the role of TGF-β isoform
signaling in early pancreatic organogenesis, demonstrating that
the developing pancreas expresses TGF-beta type II receptor (TBR-
II) and type I receptor. TBR-II localizes to ducts at later stages of
pancreatic development(Crisera et al., 1999). Blocking TGF-β sig-
naling in the embryonic pancreas, using a transgenic mouse
expressing a dominant-negative TGF-β-type-II-receptor (DNTβRII)
led to an increased number of endocrine cells arising from the
embryonic ducts. The enhanced endocrine expansion was most
prominent at E16.5, which corresponded to the normal peak of
secondary wave endocrine differentiation (Tulachan et al., 2007).
Whether adult pancreatic ducts can recapitulate the embryonic
mode of development to give rise to new β-cells remains hotly
Y. El-Gohary et al. / Developmental Biology 378 (2013) 83–9384debated(Bonner-Weir et al., 2008; El-Gohary et al., 2012;
Furuyama et al., 2011; Inada et al., 2008; Kopp et al., 2011; Solar
et al., 2009).
In vivo studies of the role of TGF-β ligands in development have
been difﬁcult since mice deﬁcient in TGF-β2 and TGF-β3 developed
severe embryonic developmental defects and 100% embryonic
lethality(Kaartinen et al., 1995; Sanford et al., 1997); therefore,
the role of TGF-β2 and TGF-β3 has been difﬁcult to assess in vivo.
Furthermore, disrupting the TGF-β1 gene leads to severe multi-
focal inﬂammatory diseases, thus confounding analyses of differ-
ent tissues (Shull et al., 1992). Using a DNTβRII transgene avoided
some of the problems associated with deletion of TGFβ ligands,
and shed some light on a possible role for TGF-β signaling in
regulating pancreatic endocrine expansion and maturation during
development(Bottinger et al., 1997; Tulachan et al., 2007).
Canonical TGF-β signaling involves ligand binding to the TGF-β-
receptor-type-II, a serine/threonine kinase receptor. Subsequently
the type II receptor recruits and phosphorylates the type I
receptors, which in turn activate downstream smad2/3 transcrip-
tion factors that mediate TGF-β-regulated gene expression
(Massague, 1998; Shi and Massague, 2003). Smad6 and smad7
are the inhibitory smads(Park, 2005; Yan et al., 2009). Smad6 is
thought to inhibit speciﬁcally those smads that are downstream of
BMP signaling, i.e. smads 1, 5, and 8(Massague and Gomis, 2006;
Park, 2005), whereas smad7 seems to be more globally active
against all receptor-activated smads (smads 1, 5, 8, plus smad2 and
smad3). Thus, smad7 is the only inhibitory smad that inhibits
smad2 and smad3, which are the TGF-beta and activin signaling
smads(Park, 2005; Yan et al., 2009).
To investigate in more depth the mechanism of enhanced
endocrine expansion in the DNTβRII mice, we speciﬁcally targeted
the intracellular mediators of TGF-β signaling, smad2 and smad3,
by analyzing smad2 conditional (Smad2fx/fx) (Ju et al., 2006) and
smad3 global mutant (exon2 deletion) mice (Datto et al., 1999).
Smad2fx/fx mice were crossed with a pdx1-cre-ERT mouse to
create tamoxifen-inducible smad2 conditional mutants for the
pancreas. Ablation of smad2 or smad3 led to a signiﬁcant increase
in endocrine cell numbers at E18. Furthermore, we generated a
smad7fx/fx knock-in mouse, conditionally deleting smad7 in the
pancreas by crossing it with pdx1-cre-ERT mice. We saw a severely
diminished number of hormone+ cells at E18.
These results implicate an important role for smad2 and smad3
in the expansion of the pancreatic endocrine compartment, and
implicate smad7 as a key regulator of this expansion, likely
through suppression of smads 2 and 3. These results should
provide a better understanding of the key control mechanisms of
β-cell development, and may provide a mechanistic link between
developmental neogenesis of pancreatic endocrine cells and pan-
creatic islet cell replication.Materials and methods
Transgenic animals and genotyping
All the animal experiments were performed in accordance with
guidelines established by the University of Pittsburgh Institutional
Animal Care and Use Committees. Smad3-exon 2 null mutant mice
were obtained from Jackson Laboratories (stock 003451), originally
made by Luis Parada UT Southwestern. Transgenic mice expressing
Smad2fx/fx were generous gifts from Dr. Erwin P. Bottinger, Mt.
Sinai School of Medicine. All transgenic mice were crossed with
Pdxcre-ER™ (Gu et al., 2002) (Mouse Models of Human Cancers
Consortium, MMHCC). Non-pancreatic tissues from the embryos
and adult mice were used for genotyping with the Extract-N-Amp
PCR mix (Sigma, St. Louis, MO) kit and PCR probe that is speciﬁcfor the transgene. Pancreata were isolated by micro-dissection
from the transgenic embryos, as well as from the littermate
controls.Tamoxifen injection
The cre-ER™/LoxP system, tamoxifen (Sigma, St Louis, MO) was
dissolved at 20 mg/ml in corn oil (Sigma) and was administered
into adult mice intraperitoneally. For embryonic studies, pregnant
females received a single dose 2 mg per 40 g body weight
intraperitoneally at E10.5 and embryonic pancreases were subse-
quently harvested at different time points. The pancreas were then
harvested and ﬁxed in 4% paraformaldehyde overnight in 4 1C then
placed in 30% sucrose overnight in 4 1C for cryoprotection. Tissues
were then embedded in Tissue-Tech O.C.T compound and then
frozen for sectioning.
Histology and immunohistochemistry
Harvested tissues were ﬁxed in 4% paraformaldehyde, cryopro-
tected in 30% sucrose overnight at 4 1C, then embedded in Tissue-
Tech O.C.T compound and frozen in −20 1C. 6–8 μm-thick frozen
sections were cut at −23 1C in a cryostat and mounted on gelatin-
coated glass microscope slides (Superfrost Plus, Fisherbrand). For
immunostaining, optimal dilutions and controls were used for
each antibody used. Insulin guinea pig anti-swine 1:500 (Dako,
Carpinteria, CA), glucagon rabbit monoclonal 1:2000 (Linco),
amylase rabbit anti-human 1:400 (Sigma, St. Louis, MO), smad7
rabbit polyclonal IgG 1:50 (Santa Cruz biotech, CA), PDX-1 rabbit
polyclonal 1:1400 (generous gift from Prof. Chris Wright, Vander-
bilt University Medical School, Nashville, TN), PDX-1 goat poly-
clonal 1:1000 (Abcam), Dolichos biﬂorus agglutinin FITC
conjugated (DBA), which binds to lectins present on ductal cells,
1:50 (Vector Laboratories, CA), anti-bromo-deoxyuridine (BrdU)
rat monoclonal antibody 1:400 (Abcam), anti-bromo-deoxyuridine
rat mono-cloncal antibody 1:100 (Novus Biologicals). Primary
antibodies were incubated for 2 h at room temperature or at 4 1C
overnight. Biotinylated Vectastain ABC kit or AMCA/CY3/FITC
ﬂuorescent conjugated donkey secondary antibodies were used
for 1.5 h at room temperature. Immunoperoxidase was detected by
DAB kit (Dako, Carpintaria, CA) or AEC (Sigma, St. Louis, MO) and
ﬂuorescently labeled samples were imaged using a ﬂuorescent
microscope. Tissue sections were viewed on an upright Axio
Imager Z1 microscope. Images were captured with the AxioCam
MRc5 and processed using AxioVs40 V4.8.2.0 software or with an
inverted Olympus Fluoview 1000 confocal microscope to confo-
cally image the tissue sections. The pictures were generated by
overlay of the colors followed by merging of all color channels
into one.
Bromo-deoxyuridine (BrdU) incorporation and cell counting
Pregnant mice were injected with BrdU (Sigma, St. Louis, MO)
200 mg/Kg intraperitoneally 4 h before harvesting the embryos
The pancreas is then ﬁxed in 4% paraformaldehyde overnight in
4 1C then placed in 30% sucrose overnight in 4 1C. Tissues were
then embedded in Tissue-Tech O.C.T compound and then frozen
for sectioning. Antigen retrieval was done on the slides by treating
with sodium citrate (10 mM, pH 6.0), heating it in the microwave
at low power for 15 min and then subsequently treating it with
2 M HCl for 35 min, followed by overnight incubation with
primary antibodies. To quantify number of BrdU positive cells in
embryonic wild-type and transgenic pancreases, the whole frozen
pancreas was sectioned 6–8 μm-thick at −23 1C in a cryostat and
mounted on gelatin-coated glass microscope slides (Superfrost
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analyzed from 2 different litters for E12.5 CD1, a total of 7 embryos
were analyzed from 2 different litters for E14.5 CD1 and a total of
7 embryos were analyzed from 1 litter for E16.5 CD1. The entire
embryonic pancreas was sectioned (100 sections total over 15
slides) and evenly distributed 6 um sections throughout the organ
were selected for analysis and quantiﬁcation. The total number of
smad7 positive cells that were BrdU positive divided by total
number of smad7 positive cells using the image tracing software
(Stereoinvestigator, Microbrightﬁeld) to count and tag individual
BrdU positive/smad7 positive cells using dapi. Using the Stereo-
investigator program, individual BrdU positive cells were tagged
and linked to Neurolucida software (MicroBrightField, Inc.) to
quantify number of cells.Morpholino antisense organ culture experiment:
Dorsal pancreatic rudiments of four E11.5 CD1 mouse embryos
were grown in hanging drop organ culture containing either
control scrambled morpholino or Smad2, Smad3, Smad7 morpho-
lino. The morpholino antisense targeting speciﬁc genes were
custom designed at www.gene-tools.com. A novel peptide based
aqueous Endo-Porter system (www.gene-tools.com) was used
according to manufacture's instructions for cytosolic delivery. A
drop consisting of 50 μl of control media with 20 mM morpholino
antisense was placed on a 35 mm Petri dish. Pancreas rudiment
was then placed inside the drop and inverted so that the drop
hangs. The bottom of the Petri dish was ﬁlled partially with media
to keep the environment moist. The drop was replaced every day
and the cultures were maintained at 37 1C and 5% CO2. The
explants were harvested at day 3 or day 7 for histological analysis
and downstream applications.Morphometric analysis and cell counting
Time-pregnant transgenic mice, Pdxcre-ER™; Smad7fx/fx,
Pdxcre-ER™; Smad2fx/fx, Pdxcre-ER™; Smad2fx/fxSmad3 exon2
were administered a single dose of tamoxifen intraperitoneally,
2 mg per 40 g body weight, at E10.5 and harvested at E18.5.
Littermates that were cre negative were used as controls. A total
of 18 embryos were analyzed from 6 different litters. The entire
embryonic pancreas was sectioned (100 sections total over 20
slides) and evenly distributed 6 um sections throughout the organ
were selected (every 5th slide, 4 slides total, were chosen for
analysis and quantiﬁcation). Twenty ﬁve sections were counted (5
sections on each slide). Total number of insulin and glucagon
positive cells was counted with dapi, using the image tracing
software (Stereoinvestigator, Microbrightﬁeld) to count and tag
individual insulin positive and glucagon positive cells. Using the
Stereoinvestigator program, individual endocrine positive cells
were tagged and linked to Neurolucida software (MicroBrightField,
Inc.) to quantify number of cells.
The embryonic pancreas for time pregnant smad3 exon2 global
knockout female mice were harvested at E18.5, with heterozygote
smad3 exon2 being used as controls. Similarly, a total of 15
embryos were analyzed from 7 different litters. The entire
embryonic pancreas was sectioned (100 sections total over 20
slides) and evenly distributed 6um sections throughout the organ
were selected (every 5th slide, 4 slides total, were chosen for
analysis and quantiﬁcation). Twenty ﬁve sections were counted (5
sections on each slide). Total insulin and glucagon area was
determined using Image J software.Results
Phospho-smad2 and phospho-smad3 expression pattern in the
developing mouse pancreas
Previous studies have shown that smads 2 and 3 are present in
the developing pancreas (Brorson et al., 2001), though the dis-
tribution of the activated phosphorylated forms (p-smads) has not
been studied. We found broad expression of p-smad2/3 in the
embryonic mouse pancreas, including expression in the mesench-
yme and epithelium at embryonic day 11 (E11) (Fig. 1A and B). Of
note, both nuclear and cytoplasmic staining was detected in the
epithelium at E11, E12, and E18 (Fig. 1 and Fig. S1A–D). Interest-
ingly, by E12.5 p-smad2/3 was found to then localize speciﬁcally in
the nucleus of newly formed glucagon+ and insulin+ cells (Fig. 1C–
F). This nuclear localization is persistent, and prominent in the
E18.5 and adult 10 week old mouse pancreas (Fig. 1E–G). This
nuclear localization suggested a stronger activity of the p-smads in
these endocrine-committed, hormone-positive cells, and such
hormone-positive cells in the early embryonic pancreas are known
to rarely be proliferative(Jensen et al., 2000). Semi-quantitative RT-
PCR (QPCR) analysis of smad and TGFβ ligand expression at serial
gestational ages revealed that smads 2, 3, and 4 as well as TGFβ1,2
and 3 all showed a rise toward the end of gestation, consistent
with a possible role in mediating the maturation of endocrine cells
(Fig. 1H,I and Fig. S1E–H). We also stained with antibodies speciﬁc
for either p-smad2 or p-smad3. These antibodies appear to have a
weaker afﬁnity for their target, and no clear signal was detectable
until E15 (Fig. S1A–D). At that time, and even more so at E18, both
of these individual p-smads were found to be localized to the
ductal and periductal/endocrine region of the central portion of
the pancreas. Thus, it seems plausible that the staining we see
with a common p-smad2/3 antibody represents a mix of both
p-smads, rather than predominantly one or the other p-smad.
In vitro inhibition of embryonic pancreas phospho-smad2/3.
In order to determine a possible role for activated (phosphory-
lated) smad2/3 in the pancreas, we ﬁrst treated E11 embryonic
pancreas in a hanging drop culture system with smad2 or smad3
morpholino antisense with an endoporter system for 5-days,
similar to previous studies (Prasadan et al., 2011) (Fig. 2). Control
ﬂuorescent morpholino antisense was found to penetrate into the
explants and into individual cells (Fig. 2A). Secondarily, Western
blotting and immunostaining against the smad proteins revealed
signiﬁcant knock-down in these explants after treatment with
morpholinos(Fig. 2B and Fig. S2A–D). Morpholinos against either
smad2 or smad3 were used, but not in combination due to
apparent toxicity of the higher total concentration of morpholinos.
Here, with inhibition of either smad2 or smad3, signiﬁcantly
enhanced numbers of insulin+ and glucagon+ cells were seen after
the 5-days in culture (Fig. 2C–E). Overall, the number of endocrine
cells (only insulin+ and glucagon+ cells were counted) increased
1.7-fold with smad2 antisense treatment, and doubled with smad3
antisense treatment (Fig. 2H, n¼4, p<0.001). The relative distribu-
tion between insulin+ and glucagon+ cells did not change sig-
niﬁcantly over the 7-day culture period, remaining in the range of
50–65% insulin cells (data not shown). In addition, more than
double the percentage of endocrine cells were BrdU+ after treat-
ment with smad2 or smad3 antisense (Fig. 2J n¼3, p<0.005, Fig.
S22E–G). This result suggests that inhibition of smad2/3 may be a
normal, endogenous mechanism to allow for proliferation of
endocrine hormone-positive cells, further suggesting that the
increased numbers of endocrine cells was due to enhanced
proliferation. Furthermore, QPCR analysis revealed a signiﬁcant
upregulation of the endocrine progenitor markers, neuroD and
Fig. 1. Ontogeny of phospho-smad2/3 (p-smad2/3) expression in the embryonic pancreas. (A and B) p-smad2/3 is expressed fairly diffusely in both epithelium and
mesenchyme early in pancreatic development (E11.5). (C and D) However, by E12.5 the cells that have committed to become endocrine, as evidenced by staining for
hormones (here, insulin and glucagon), have focal nuclear localization (dotted lines outline endocrine cluster). (E and F) This nuclear-speciﬁc pattern persisted at E18.5.
(G) 10 week old adult pancreas, p-smad2/3 is strongly localized to the nuclei of all islet cells. (H) QPCR ontogeny for smad2 at different stages of embryonic development
(n¼5, (n) p<0.002, (n)(n)p<0.003, (n)(n)(n)p¼0.007, (n)(n)(n)(n)p¼0.03, 7S.D). (I) QPCR ontogeny for smad3 at different stages of embryonic development (n¼5, (n)p<0.02,
(n)(n)p<0.03, (n)(n)(n)p<0.04, 7S.D.). Scale bar (A–D, G) is 10 μm, (E and F) is 20 μm.
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Fig. 2. Morpholino culture experiments with E11.5 pancreas. (A) Wholemount E11.5 pancreas with FITC-tagged morpholino in culture showing penetration of explant by
morpholinos, with the inset demonstrating a histologic section of the cultured E11.5 pancreas with FITC-tagged morpholino within the pancreatic epithelium. (B) Western
blot showing the effective knockdown of smad2, smad3 and smad7 with morpholino treatment compared to control. (C and F) Control morpholino of an E11.5 pancreas
harvested and placed in culture for 5days revealing baseline expression of insulin, glucagon and amylase. (D) When smad2 morpholino was added to an E11.5 pancreas and
cultured for 5days, a signiﬁcant increase in the endocrine compartment was observed. (E) This signiﬁcant expansion in the endocrine compartment was even more
pronounced when smad3 mopholino was added to the E11.5 pancreatic culture. (G) The addition of smad7 morpholino to the cultured E11.5 pancreas led to a signiﬁcant
decrease in the endocrine compartment. (H and I) Quantitative analysis of the total endocrine area with smad2, smad3 and smad7 morpholino compared to control (n¼4,
p<0.001, 7SEM). (J) Quantitative proliferative analysis of the percentage of endocrine cells in cultured E11.5 pancreas that were BrdU+ after adding smad2 or smad3 or
smad7 morpholino (n¼3, p<0.005, 7SEM). Scale bar: 20 μm.
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endocrine cells (Fig. S2K and L). This result suggests that inhibition
of smad2/3 may be an endogenous mechanism for allowing
proliferation of endocrine hormone-positive cells.
To try to understand the mechanism by which there was
greater formation of endocrine cells, we harvested tissues after
only 36 h of culture and saw a similar increase (2–3 fold) in the
number of pax6+/glucagon+ double-positive cells in smad2 anti-
sense and smad3 antisense treated explants (Fig. S2M–O). Thisearly increase suggests that smad2 and smad3 normally act to
suppress recruitment of new progenitors in addition to affecting
endocrine cell maturation. The presence of these smads through-
out the early (E11–E12) epithelium (Fig. 1A) would also be
consistent with this role. Furthermore, by day 3 of culture, we
saw a large number of BrdU +/Nkx2.2+ cells, suggesting that the
endocrine progenitors continued to expand inappropriately due to
blocked smad2/3 (data not shown), again particularly pronounced
with smad3 antisense treatment.
Fig. 3. (A–D) Insulin and glucagon expression pattern in E18 pdx1-cre-ERT;smad2fx/fx pancreas compared with littermates that are Cre negative. (E) Quantiﬁcation of the
number of endocrine cells in E18 pdx1-cre-ERT;smad2fx/fx pancreas (n¼5, (n)p<0.0002, (n)(n)p<0.0001, 7SEM). (H) Quantiﬁcation of endocrine cells in smad3-exon2−/− and
smad3-exon2+/− E18 pancreas (n¼3, (n)p<0.05, (n)(n)p¼0.02, (n)(n)(n)p<0.04, 7SEM. Scale bar is 20 μm.
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To expand on these in vitro observations of the role of smad2
and 3 in embryonic pancreatic differentiation, we then obtained
smad2 conditional (Smad2fx/fx ) (Ju et al., 2006) and smad3 global
mutant (exon2 deletion) mice(Datto et al., 1999). Smad3−/− (exon2)
global null mutant mice are viable and fertile (Datto et al., 1999),
and to our knowledge no smad3 conditional mutant mice exist.
Smad2fx/fx mice were crossed with a pdx1-cre-ERT mouse to
create tamoxifen-inducible smad2 conditional mutants for the
pancreas. For smad2 mutants, tamoxifen was given at E10.5 of
gestation. In pdx1-cre-ERT;R26R-lsl-lacZ embryos, consistent with
previous reports (Gu et al., 2002), we conﬁrmed that by E13.5
essentially all (>95%) of pancreatic epithelial and endocrine cellswere lineage-tagged after the single E10.5 tamoxifen injection
(data not shown). Quantiﬁcation of the number of endocrine cells
in the smad mutant animals revealed that at E15 there were no
signiﬁcant differences in the number of pancreatic endocrine cells
between mutant smad2 or smad3 mice and littermate controls,
and no difference in the percentage of BrdU positive cells (data not
shown). By E17-18, however, signiﬁcant increases in the number of
endocrine cells were seen with ablation of smad2 (Fig. 3A–E) or
smad3 (Fig. 3H). In pdx1-cre-ERT;smad2fx/fx conditional mutants,
there was a 30% increase in the number of endocrine cells (insulin+
or glucagon+ only, other endocrine cells made up only a small
fraction of the cells present), which consisted of a 20% increase in
the number of insulin-positive cells, and a 40% increase in the
number of glucagon-positive cells (Fig. 3E). In smad3−/− mice there
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a relatively equal percentage increase in insulin+ and glucagon+
cells (Fig. 3H). This endocrine augmentation, especially with the
greater pro-endocrine effect in smad3 mutants than in smad2
mutants, is similar to our ﬁndings with the in vitro antisense
inhibition (data not shown). We did not see an additive effect
between these two mutations, as mice bred to be pancreatic
double smad mutants (pdx1-cre-ERT;smad2fx/fx; smad3−/−),
showed a phenotype similar to the smad3−/− mutants (data not
shown). Thus, given that we found that both smads are expressed
in the endocrine progenitor pool, it seems likely that both smads
are necessary for endocrine maturation, and absence of these
smads leads to an inappropriate expansion of immature pancreatic
endocrine cells, and thus the two smads may work in a synergistic
or overlapping way.
Expression of smad7 during pancreatic development
Because of the known role of smad7 as an inhibitor of smad
signaling(Park, 2005; Yan et al., 2009), and since smad7 over-
expression, but not smad6 overexpression in the developing
pancreas led to pancreatic endocrine hypoplasia(Goulley et al.,
2007; Smart et al., 2006), we wished to examine the presence and
role of endogenous smad7 in the pancreas. To better characterize
these smad7+ cells during embryonic development, we performed
confocal immunoﬂuorescence for smad7. Smad7 was present
throughout the early (E13.5) pancreatic epithelium, both by
immunohistochemistry and by in situ hybridization (Fig. 4A–E
and J). By QPCR, however, this expression seemed relatively low,
and then was upregulated late in gestation (Fig. 4I), perhaps due to
an increased contribution from acinar cells (see below and Fig. 6C).
Most of the smad7-expressing cells in the younger embryo (E13.5)
co-localized with E-cadherin+ epithelial cells, but a few were
hormone+ endocrine cells (Fig. 4A–E), perhaps representing imma-
ture newly-formed endocrine cells. Interestingly, as development
progressed (E15.5), the smad7 co-localization with the hormone+
endocrine cells was diminished and weaker, but persisted in the E-
cadherin+/hormone− cells (Fig. 4F–H, K, L and Fig. 6C). This
transition of smad7 expression from being positive in a few early
hormone-positive, presumably more immature endocrine cells at
E13.5 to being diminished in late-gestational, presumably more
mature hormone-positive cells, is consistent with a role for smad7
in suppressing smad2/3 in immature endocrine cells. Then, as
smad7 shuts off, the endocrine cells are able to mature in
association with smad2/3 activity. Consistent with this observa-
tion, we saw that many smad7+ cells were BrdU+ throughout
gestation (Fig. 5A–F), and many smad7+ cells co-stained for ngn3+
(Fig. 5J–L), marking a proliferative endocrine progenitor pool.
Interestingly, smad7+ cells typically did not co-stain for neuroD
(Fig. 5G–I), a marker of post-mitotic endocrine lineage cells,
consistent with smad7 serving to maintain the proliferative state
of the immature endocrine cells. Later in gestation, at E16.5 and at
P7, the acinar tissue was positive for smad7 (Fig. 5E,F and Fig. 6C),
which may explain the high levels of smad7 by QPCR (Fig. 4I), and
may reﬂect the fact that the acinar population is rapidly prolif-
erative in late gestation. At E16 the ducts and some endocrine cells
were weakly positive for smad7 (Fig. 6A). By post-natal day 7 (P7),
smad7 was almost exclusively localized to the acinar tissue (Fig. 6B
and C).
Smad7 inhibition in vitro or in vivo leads to suppression of endocrine
development
When cultured E11.5 embryonic pancreas explants were trea-
ted with morpholino antisense against smad7, we saw a diminu-
tion in the number of endocrine cells and in the endocrine-positive area in the explants after 7-days in culture (Fig. 2F, G
and I n¼4, p<0.001). These results suggest that smad2/3 inhibition
may normally prevent premature endocrine maturation, and thus
allow for endocrine progenitor expansion. As with the smad2/3
antisense inhibition earlier, Western blot conﬁrmed smad7 knock-
down by the antisense (Fig. 2B). BrdU analysis revealed that there
was a marked decrease in the percentage of endocrine cells that
were BrdU+ (insulin and glucagon only were quantiﬁed) (Fig. 2J,
Fig. S2H).
To determine a possible role for smad7 in pancreatic endocrine
cell development, we generated a smad7fx/fx knock-in mouse.
These mice were created with loxP sites ﬂanking exon5 (the
TGF-β receptor interacting domain) (Park, 2005; Yan et al., 2009,
El-Gohary et al., Unpublished date) of the smad7 locus. We then
conditionally deleted smad7 in the pancreas by crossing the
smad7fx/fx mice with pdx1-cre-ERT mice to allow tamoxifen-
inducible ablation of smad7 in embryonic pancreatic epithelial
cells and in developing islets, acini, and ducts. We gave tamoxifen
at E10.5. We saw no phenotypic effect early on, at E13-15, but by
E17.5, similar to smad7 antisense inhibition in vitro, we saw
diminished numbers of hormone+ cells (insulin and glucagon)
(Fig. 6I). Here again, consistent with a role for smad7 in suppres-
sing premature maturation of endocrine cells, we saw a signiﬁcant
decrease in the number of (presumably immature) mafB+/insulin+
double-positive cells (Fig. 6G, H, J–L). MafB+/insulin+ cells have
been proposed as an immature β-cell, and as the cells mature mafB
is turned off and mafA turned on (Artner et al., 2010).Discussion
Here we have detailed a mechanism that regulates embryonic
pancreatic endocrine expansion and maturation, involving a smad
signaling network. This regulation is achieved through the intra-
cellular smads 2, 3, and 7. TGF-β superfamily signaling has been
shown to play an important role in regulating many develop-
mental and physiologic processes in the pancreas and in the β-cell
(Goto et al., 2007; Harmon et al., 2004; Kim et al., 2000; Miralles
et al., 1998a, 1998b; Rane et al., 2006; Ritvos et al., 1995; Sanvito
et al., 1994; Shi and Massague, 2003; Tulachan et al., 2007; Zhang
et al., 2004, 2008). We have previously reported that signals
mediated through TGF-β-receptor-II to the embryonic ductal
structures suppress the recruitment of endocrine progenitors
and suppress their proliferation (Tulachan et al., 2007). We show
here that these signals appear to be mediated by the intracellular
signaling molecules, smad2 and smad3, which are downstream
effectors of TGF-β-receptor-II (Shi and Massague, 2003).
These same smads are potential regulators of the transdiffer-
entiation of AR42J cells (a duct cell line) into β-cells in vitro (Yew
et al., 2004; Zhang et al., 1999). In keeping with the results that we
now show here, heterozygous smad2 global null mutant mice
(smad2+/−) have been shown to have increased numbers of ngn3+
progenitor cells (Harmon et al., 2004), and increased numbers of
nkx2.2+ and nkx6.1+ progenitor cells (Harmon et al., 2004)
(homozygous global smad2−/− mutant mice are early embryonic
lethal (Nomura and Li, 1998)). The signiﬁcant increase in endocrine
cell number that we found at E18 with smad2 and/or smad3
deletion, coupled with the normal strong nuclear localization of
p-smad2/3 in hormone positive cells at E12.5 (Fig. 1C and D), E18.5
(Fig. 1E and F) and 10wks (Fig. 1G) supports the notion that
inhibiting smad2/3, and thus TGF-β signaling, may be an endo-
genous mechanism for allowing proliferation of β-cells. Further-
more, semi-quantitative RT-PCR analysis of smad expression
revealed that smads 2, 3, and 4 all showed a rise toward the end
of gestation, consistent with a possible role in mediating the
maturation of endocrine cells (Fig. 1H, I and S1E).
Fig. 4. Ontogeny of smad7 expression in the embryonic pancreas. (A–E). Smad7 is initially expressed throughout the pancreatic epithelium during early pancreatic
development (E13.5), including co-expression with insulin positive cell. (F–H) During later embryonic pancreatic development (E15.5), insulin-positive cells no longer co-
express smad7. (I) QPCR ontogeny for smad7 at different stages of embryonic development (n¼5, (n)p<0.001, (n)(n)p<0.0001, (n)(n)(n)p<0.001, (n)(n)(n)p<0.002, 7S.D.). Smad7 in-
situ hybridization in E13.5 pancreas (J) and in E15.5 pancreas (K), with E15.5 insulin counterstaining in (L). Scale bar, (A and B) is 10 μm, (C–H) is 20 μm, (J–L) is 50 μm.
Y. El-Gohary et al. / Developmental Biology 378 (2013) 83–9390Our results show an important regulatory role for smad7 in
both developmental endocrine differentiation, and maturation.
Although there are two known inhibitory smads, smad6 and
smad7, we believe the effects here are speciﬁc to smad7. Smad6
is thought to be a speciﬁc inhibitor of the BMP smads 1,5, and 8
(Massague and Gomis, 2006; Park, 2005; Yan et al., 2009).
Transgenic overexpression of smad6 under the pdx1 promoter
showed no developmental phenotype, and in the adult there was
mainly only an effect on insulin secretion (Goulley et al., 2007)
rather than an effect on islet growth. Smad7, on the other hand,
can inhibit both the BMP smads (1,5, 8) and the TGF-β and activinsmads (2/3) (Massague and Gomis, 2006; Park, 2005; Yan et al.,
2009). Thus, phenotypes attributable to alterations of smad7, but
not smad6, would likely be due to effects on smad2/3 signaling.
When Smart et al. transgenically overexpressed smad7 under the
pdx1 promoter in a tetracycline-regulatable system to thus create
an inducible inhibition of smad signaling in pdx1-expressing cells
(Smart et al., 2006), there was an enhanced number of glucagon
cells, but a drastically reduced number of β-cells. This latter study
could contradict ours. However, since smad7 was expressed under
the pdx1 promoter, coupled with the fact that pdx1 expression is
typically down-regulated as embryonic pancreatic epithelial cells
Fig. 5. Proliferation analysis of smad7-expressing cells in the embryonic pancreas. (A and F) Proliferating smad7 cells during embryonic development. (A and B) At E12.5,
49.4%74.3 SD, n¼7, smad7 positive cells are BrdU positive. (C and D) At E14.5, 55.4%74.3 SD, n¼7, smad7 positive cells are BrdU positive. (E–F) At E16.5, 26.5%73.6 SD,
n¼7, smad7 positive cells are BrdU positive. (G–I) NeuroD positive cells speciﬁcally do not coexpress smad7 at E16.5 (arrows), with none of the 6,727 NeuroD-positive cells
from 7 embryos co-localizing with smad7. (J–L) Ngn3 positive cells co-express smad7 in pancreatic epithelium at E16.5 (arrow), with 17.1%73.4 SD, n¼5, of Ngn3 positive
cells co-localizing with smad7 positive cells. Scale bar, (A–F) and (J–L) is 10 μm, (G–I) is 20 μm.
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Fig. 6. Smad7 initially co-localizes with DBA positive ducts at E16 (A), and then is absent from the ducts by P7 (B and C). (I) Quantiﬁcation of the number of endocrine cells in
E18.5 pdx1-cre-ERT;smad7fx/fx pancreas following tamoxifen treatment at E10.5 (n¼5, (n)p<0.0001, (n)p¼0.0001, 7S.D). (G, H, J and K) Insulin and mafB co-expressing cells
are diminished in E18 pdx1-cre-ERT;smad7fx/fx pancreas, quantiﬁed in (L) (n¼5, (n)p<0.0001, 7SEM). Scale bar, (A–F) is 10 μm, (I,J, L and M) is 20 μm.
Y. El-Gohary et al. / Developmental Biology 378 (2013) 83–9392commit to becoming endocrine progenitor cells, it would suggest
that the transgenic smad7 would not be strongly expressed in
endocrine progenitors. Therefore, phenotypic effects of forced
smad7 overexpression in early pancreatic epithelium may have
effects on endocrine cell formation only as an epiphenomenon.
Thus, we have identiﬁed an important and necessary regula-
tory point for proper β-cell expansion in the form of a smad2/3/7
network. This pathway could represent a legitimate target forregulating β-cell proliferation, and for generating more β-cells for
the future treatment of diabetes.Statistical analysis
Statistical signiﬁcance was determined by two-tailed Student's
t-test.
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